🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Enimmune Corporation (TPEX:6564)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
13.60
-1.10 (-7.48%)
Nov 20, 2026, 1:50 PM CST

Enimmune Statistics

Total Valuation

Enimmune has a market cap or net worth of TWD 981.02 million. The enterprise value is 968.15 million.

Market Cap981.02M
Enterprise Value 968.15M

Important Dates

The next estimated earnings date is Thursday, November 26, 2026.

Earnings Date Nov 26, 2026
Ex-Dividend Date n/a

Share Statistics

Enimmune has 72.13 million shares outstanding. The number of shares has decreased by -2.64% in one year.

Current Share Class 72.13M
Shares Outstanding 72.13M
Shares Change (YoY) -2.64%
Shares Change (QoQ) n/a
Owned by Insiders (%) 0.80%
Owned by Institutions (%) 3.87%
Float 30.80M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 18.35
PB Ratio 9.77
P/TBV Ratio 258.03
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales 18.11
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 1.01, with a Debt / Equity ratio of 1.59.

Current Ratio 1.01
Quick Ratio 0.83
Debt / Equity 1.59
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage -27.71

Financial Efficiency

Return on equity (ROE) is -74.45% and return on invested capital (ROIC) is -23.84%.

Return on Equity (ROE) -74.45%
Return on Assets (ROA) -26.25%
Return on Invested Capital (ROIC) -23.84%
Return on Capital Employed (ROCE) -91.11%
Weighted Average Cost of Capital (WACC) 5.16%
Revenue Per Employee n/a
Profits Per Employee n/a
Employee Count 38
Asset Turnover 0.12
Inventory Turnover 1.60

Taxes

Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -33.33% in the last 52 weeks. The beta is 0.25, so Enimmune's price volatility has been lower than the market average.

Beta (5Y) 0.25
52-Week Price Change -33.33%
50-Day Moving Average 15.66
200-Day Moving Average 17.19
Relative Strength Index (RSI) 40.09
Average Volume (20 Days) 60,755

Short Selling Information

Short Interest n/a
Short Previous Month n/a
Short % of Shares Out n/a
Short % of Float n/a
Short Ratio (days to cover) n/a

Income Statement

In the last 12 months, Enimmune had revenue of TWD 53.45 million and -120.88 million in losses. Loss per share was -1.68.

Revenue53.45M
Gross Profit 4.31M
Operating Income -124.27M
Pretax Income -120.88M
Net Income -120.88M
EBITDA -117.77M
EBIT -124.27M
Loss Per Share -1.68
Full Income Statement

Balance Sheet

The company has 172.45 million in cash and 159.57 million in debt, with a net cash position of 12.88 million or 0.18 per share.

Cash & Cash Equivalents 172.45M
Total Debt 159.57M
Net Cash 12.88M
Net Cash Per Share 0.18
Equity (Book Value) 100.39M
Book Value Per Share 1.39
Working Capital 3.74M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -83.45 million and capital expenditures -2.75 million, giving a free cash flow of -86.19 million.

Operating Cash Flow -83.45M
Capital Expenditures -2.75M
Depreciation & Amortization 6.50M
Net Borrowing -8.19M
Free Cash Flow -86.19M
FCF Per Share -1.19
Full Cash Flow Statement

Margins

Gross margin is 8.06%, with operating and profit margins of -232.49% and -226.16%.

Gross Margin 8.06%
Operating Margin -232.49%
Pretax Margin -226.16%
Profit Margin -226.16%
EBITDA Margin -220.33%
EBIT Margin -232.49%
FCF Margin n/a

Dividends & Yields

Enimmune does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
FCF Payout Ratio n/a
Buyback Yield 2.64%
Shareholder Yield 2.64%
Earnings Yield -12.35%
FCF Yield -8.79%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number n/a
Graham Upside n/a
Graham Formula Value n/a
Graham Formula Upside n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

Enimmune has an Altman Z-Score of -0.38 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score -0.38
Piotroski F-Score 2